Donald J Johann Jr
Overview
Explore the profile of Donald J Johann Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
620
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gong B, Li D, Labaj P, Pan B, Novoradovskaya N, Thierry-Mieg D, et al.
Sci Data
. 2024 Aug;
11(1):892.
PMID: 39152166
Next-generation sequencing (NGS) has revolutionized genomic research by enabling high-throughput, cost-effective genome and transcriptome sequencing accelerating personalized medicine for complex diseases, including cancer. Whole genome/transcriptome sequencing (WGS/WTS) provides comprehensive insights,...
2.
Shin I, Tangrea M, Emmert-Buck M, Johann Jr D
Methods Mol Biol
. 2024 Jul;
2823:55-75.
PMID: 39052214
Combining proteogenomics with laser capture microdissection (LCM) in cancer research offers a targeted way to explore the intricate interactions between tumor cells and the different microenvironment components. This is especially...
3.
Li D, Wang D, Johann Jr D, Hong H, Xu J
Exp Biol Med (Maywood)
. 2023 Dec;
248(21):1918-1926.
PMID: 38062992
Tumor mutational burden (TMB), when at a high level, is an emerging indicative factor of sensitivity to immune checkpoint inhibitors. Previous studies have shown that the more affordable and accurate...
4.
Zhang Y, Blomquist T, Kusko R, Stetson D, Zhang Z, Yin L, et al.
Genome Biol
. 2022 Jun;
23(1):141.
PMID: 35768876
Background: Clinical laboratories routinely use formalin-fixed paraffin-embedded (FFPE) tissue or cell block cytology samples in oncology panel sequencing to identify mutations that can predict patient response to targeted therapy. To...
5.
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
Willey J, Morrison T, Austermiller B, Crawford E, Craig D, Blomquist T, et al.
Cell Rep Methods
. 2022 Apr;
1(7):100106.
PMID: 35475002
The primary objective of the FDA-led Sequencing and Quality Control Phase 2 (SEQC2) project is to develop standard analysis protocols and quality control metrics for use in DNA testing to...
6.
Gong B, Deveson I, Mercer T, Johann Jr D, Jones W, Tong W, et al.
Sci Data
. 2022 Apr;
9(1):170.
PMID: 35418127
Recently we reported the accuracy and reproducibility of circulating tumor DNA (ctDNA) assays using a unique set of reference materials, associated analytical framework, and suggested best practices. With the rapid...
7.
Li D, Kusko R, Ning B, Tong W, Johann Jr D, Xu J
Precis Cancer Med
. 2022 Mar;
4.
PMID: 35282311
Cancer is the second leading cause of mortality worldwide despite tremendous advances in treatment. The promise of precision oncology depends on accurate characterization of tumor mutations and subsequent therapy selection....
8.
Johann Jr D, Laun S, Shin I, Weigman R, Stephens O, Roberge A, et al.
Methods Mol Biol
. 2022 Jan;
2394:93-107.
PMID: 35094324
Improving the utilization of tumor tissue from diagnostic biopsies is an unmet medical need. This is especially relevant today in the rapidly evolving precision oncology field where tumor genotyping is...
9.
Ma L, Peterson E, Shin I, Muesse J, Marino K, Steliga M, et al.
Front Big Data
. 2021 Oct;
4:725095.
PMID: 34647017
Accuracy and reproducibility are vital in science and presents a significant challenge in the emerging discipline of data science, especially when the data are scientifically complex and massive in size....
10.
Jones W, Gong B, Novoradovskaya N, Li D, Kusko R, Richmond T, et al.
Genome Biol
. 2021 Apr;
22(1):111.
PMID: 33863366
Background: Oncopanel genomic testing, which identifies important somatic variants, is increasingly common in medical practice and especially in clinical trials. Currently, there is a paucity of reliable genomic reference samples...